222 results
PX14A6G
Chevedden John
26 Mar 24
Letter to shareholders
2:31pm
of this proposal topic being on the ABBV ballot for the next 10-years.
Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities … ; the shareholder is not able to vote your proxies, nor does this communication contemplate such an event.
The shareholder asks all shareholders to vote by following the procedural instructions provided in the proxy materials.
DEFA14A
ABBV
Abbvie Inc
18 Mar 24
Additional proxy soliciting materials
4:17pm
Materials
Soliciting Material under §240.14a-12
AbbVie Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement … , if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee paid previously with preliminary materials
8-K
EX-1.1
wjukyg2oeacy
26 Feb 24
Other Events
5:08pm
424B5
ul974yv
26 Feb 24
Prospectus supplement for primary offering
6:12am
424B5
745f7ul
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
quvba twwsft5
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
2az21 mn1d8544k4dh
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
t1e3r eimu0enkuozuy
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.2
nmhe9i6e 7k23y
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
SD
EX-1.01
scksalp96lnv
31 May 23
Conflict minerals disclosure
4:59pm